Key Insights
Nomura has set a target price of ₹1,600 for Dr. Reddy's Laboratories, implying a 26% upside, driven by expectations of double-digit revenue growth and improved margins from the launch of generic Semaglutide in Canada.
Cipla is projected to achieve a U.S. quarterly revenue run-rate of $250 million by Q4 FY27, with a target price of ₹1,510, reflecting a 17% upside, supported by high-value launches in respiratory and peptide segments.
Crompton Greaves Consumer Electricals has a target price of ₹335, indicating an 18% upside, with anticipated 14% growth in Electrical Consumer Durables (ECD) for FY27, driven by increased demand and expansion into new categories like Solar and Wires.
AI Analysis
Nomura's 'Buy' ratings for Dr. Reddy's Laboratories, Cipla, and Crompton Greaves Consumer Electricals are based on strong growth drivers and strategic...
Market Outlook
Short-Term
In the short term (1-3 months), these stocks may experience increased volatility as investors react to upcoming product launches, regulatory approvals, and quarterly earnings reports.
Long-Term
Recent News
Continue your research
Keep researching Nomura Top Stock Picks Cipla Dr Reddys Lab Crompton Greaves
Move from the topic summary into related coverage, article-level impact analysis, and the next scheduled catalyst.
Explore market intelligence
Connect this story to current themes across macro, equities, commodities, and risk.
Follow AI financial news
Find related coverage ranked around the assets and market themes you follow.
Analyze a market story
Review sentiment, relevance, likely impact, timeframe, confidence, and uncertainty.
Prepare for market events
Check scheduled catalysts and create event-specific email reminders with optional AI context.
Unlock the full Nomura Top Stock Picks Cipla Dr Reddys Lab Crompton Greaves analysis
Get AI-powered insights, alerts, and market analysis for Nomura Top Stock Picks Cipla Dr Reddys Lab Crompton Greaves and other topics you follow.
No credit card required